Cellectis SA (ALCLS):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Cellectis SA (ALCLS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7841
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellectis SA (Cellectis) is a clinical-stage biopharmaceutical company that research, develop and commercialise rational genome engineering technologies. The company pioneers gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It develops treatment based on allogeneic T-cell for the treatment of cancer. Cellectis therapeutic pipeline products include products for hematopoietic tumors such as UCART19, UCART123, UCART33, UCART-BCMA and UCART38; and products for solid tumors including UCART5T4, UCART-EgfrVIII, s-3, s-4, s-5,s-6, and s-7. The company carries out research and development in the field of oncology and gene editing. It operates in New York and Paris. Cellectis is headquartered in Paris, France.

Cellectis SA (ALCLS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellectis SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellectis SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Cellectis SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cellectis SA, Medical Equipment, Deal Details 10
Partnerships 10
Cellectis bioresearch Enters Into Technology Integration Agreement With Stemgent 10
Equity Offering 11
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 11
Cellectis Completes Private Placement Of Shares For USD24.6 Million 13
Acquisition 14
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 14
Cellectis SA – Key Competitors 15
Cellectis SA – Key Employees 16
Cellectis SA – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 01, 2018: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 18
May 07, 2018: Cellectis Reports 1st Quarter 2018 Financial Results 22
Mar 12, 2018: Cellectis Reports 4th Quarter and Full Year 2017 Financial Results 25
Nov 13, 2017: Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 29
Aug 02, 2017: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 33
May 09, 2017: Cellectis Reports 1st Quarter 2017 Financial Results 35
Mar 06, 2017: Cellectis Reports 4th Quarter and Full Year 2016 Financial Results 37
Corporate Communications 40
Aug 22, 2018: Calyxt appoints Dr. Yves J. Ribeill as Interim CEO 40
Aug 02, 2018: Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer 41
Mar 13, 2018: Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor 42
Dec 04, 2017: Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development 43
Dec 04, 2017: Cellectis Appoints Immuno-Oncology Leader Stephane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer 44
Oct 04, 2017: Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer 45
Jun 28, 2017: Cellectis Appoints Rainer Boehm, M.D. and Herve Hoppenot to Board of Directors 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Cellectis SA, Medical Equipment, Key Facts, 2017 2
Cellectis SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellectis SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellectis SA, Deals By Market, 2012 to YTD 2018 8
Cellectis SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cellectis bioresearch Enters Into Technology Integration Agreement With Stemgent 10
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 11
Cellectis Completes Private Placement Of Shares For USD24.6 Million 13
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 14
Cellectis SA, Key Competitors 15
Cellectis SA, Key Employees 16
Cellectis SA, Subsidiaries 17

List of Figures
Cellectis SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellectis SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellectis SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Cellectis SA (ALCLS):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kemwell Biopharma Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Kemwell Biopharma Pvt Ltd (Kemwell) formerly Kemwell Pvt Ltd, a subsidiary of Recipharm AB is a healthcare solutions provider that offers product development and manufacturing solutions. The organization provides contract pharmaceutical development and manufacturing organization and concentr …
  • GenSight Biologics SA (SIGHT):製薬・医療:M&Aディール及び事業提携情報
    Summary GenSight Biologics SA (GenSight) is a clinical stage biotechnology company that discovers and develops novel therapies for mitochondrial and neurodegenerative diseases. The company’s product pipeline comprises GS010 and GS030 developed for the treatment of retinal degenerative diseases. It d …
  • Synopsys, Inc.:企業のM&A・事業提携・投資動向
    Synopsys, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Synopsys, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Microbiotix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Microbiotix Inc (Microbiotix) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of infectious diseases. The company provides products for hepatitis C virus and human cytomegalovirus including HCV NS5B MBX-700, MBX-701 and MBX-400. It also provi …
  • Vascular Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Vascular Pharmaceuticals Inc (VPI) is a biotechnology company that develops and commercializes therapeutics for the treatment of diabetes associated complications. The company develops pre clinical product candidate, VPI-2690B, for treating diabetic nephropathy. Its lead compound is a humani …
  • Ahli Bank Qsc
    Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report Summary Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Louis Dreyfus Company B.V.:企業の戦略的SWOT分析
    Louis Dreyfus Company B.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Weyerhaeuser Co (WY):企業の財務・戦略的SWOT分析
    Weyerhaeuser Co (WY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • First Light Diagnostics Inc:企業の製品パイプライン分析
    Summary First Light Diagnostics Inc (FLD) is a medical device company that develops and manufactures automated medical diagnostic products for the detection of healthcare associated infections. The company’s product includes multipath analyzer system. Its multipath analyzer system detects resistant …
  • Flint Hills Resources LLC:企業の戦略的SWOT分析
    Flint Hills Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sagent Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Sagent Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sagent Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • University of Michigan:企業のM&A・事業提携・投資動向
    University of Michigan - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's University of Michigan Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Global Telecom Holding S.A.E. (GLTD):企業の財務・戦略的SWOT分析
    Global Telecom Holding S.A.E. (GLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Exact Holding N.V.:企業の戦略的SWOT分析
    Exact Holding N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • DiamondRock Hospitality Co:企業のM&A・事業提携・投資動向
    DiamondRock Hospitality Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DiamondRock Hospitality Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • InVitae Corp (NVTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company’s portfolio of diagnostic t …
  • University of Birmingham-製薬・医療分野:企業M&A・提携分析
    Summary University of Birmingham is an academic research university that offers educational services. The university provides undergraduate, postgraduate, postgraduate research, and distance learning programs. It offers educational courses in various fields including accounting, astronomy, computer …
  • U.S. Geothermal Inc. (HTM):企業の財務・戦略的SWOT分析
    U.S. Geothermal Inc. (HTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Bush Industries Inc:企業の戦略・SWOT・財務分析
    Bush Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Bush Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Twilio Inc (TWLO):企業の財務・戦略的SWOT分析
    Twilio Inc (TWLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆